This company is on a mission to beat cancer so they already started working in New York and Israel. Immunai s clandestine research may present a new technology to check the immune status of an individual. Noam Solomon and Luis Voloch had a keen interest in computational biology and engineering.
Ansuman Satpathy worked as a professor in cancer immunology at Stanford University. Danny Wells works as a data scientist at Parker Institute for Cancer. All the genius minds worked together to chalk out a plan for Immunai. Immunai looks forward to shake hands with numerous biopharma companies.
The scientific basis of it can be conceptually explained as follows- An important function of the immune system is its ability to tell between “self” and “foreign”. Checkpoint inhibitors target these checkpoints and prevent the programmed cell death. Programmed cell death protein 1 regulates and helps in this regard. So the whole idea is to build up PD1 blockade related drugs.
How T cells fight cancer following PD-1 blockade is already published by this team. The team is focusing hard on the checkpoint inhibitors.” Immunai” is working on finding new combinations and targets.
This combination of hardware and software uses single-cell profiling and hence mapping the entire immune system at its best. The idea is to get to know the physiology and pathology and hence discovering new drugs.
Cancer is very commonly inflicted disease. The dreadful results of these diseases results in adverse psychosocial impact on the patient. The blockade of PD-1 allows T cells to mediate adequate immune response. Cancer therapy is changing the practice of medicine and offering new protocols for treatment. It’s important to study the complex immune system and develop protocols for management. It’s also important to study the various cancer Biomarkers.
The road ahead
The company has signed up a seven-figure contract with Future 100 Company. The whole idea is to use an analytical approach to come up with the best possible technology to manage cancer comprehensively. The road may not be easy for Solomon but there is certainly a ray of hope for the development of better drugs for treating cancer patients. The company has already tied up with leading health centers to collaborate with effective research.